Home
TVTX
TVTX News

Latest Travere Therapeutics Inc. (TVTX) News on January 19, 2025

Travere Therapeutics Provides Corporate Update and 2025 Outlook

GlobeNewswire

6 days ago

Travere Therapeutics Provides Corporate Update and 2025 Outlook

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

12 days ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

18 days ago

High Growth Tech Stocks in the United States to Watch

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain

Simply Wall St.

24 days ago

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

2 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks in the United States

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

2 months ago

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire

2 months ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 months ago

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

2 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...

GuruFocus.com

3 months ago

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...

Travere Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Travere Therapeutics Reports Third Quarter 2024 Financial Results

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

3 months ago

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

TipRanks

3 months ago

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

GlobeNewswire

3 months ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

GlobeNewswire

3 months ago

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CNW Group

3 months ago

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire

3 months ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com

3 months ago

Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

Insider Monkey

3 months ago

Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

Exploring 3 High Growth Tech Stocks in the United States

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks in the United States

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

GlobeNewswire

4 months ago

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire

4 months ago

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

GlobeNewswire

4 months ago

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

High Growth Tech Stocks To Watch In September 2024

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In September 2024

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

GlobeNewswire

5 months ago

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

5 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

Travere Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Travere Therapeutics to Report Second Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

GlobeNewswire

6 months ago

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago

Simply Wall St.

7 months ago

Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intermediate Capital Group plc: Notification of Transactions of Directors

GlobeNewswire

7 months ago

Intermediate Capital Group plc: Notification of Transactions of Directors

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

ACCESSWIRE

7 months ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Lyft stock earns multiple upgrades after investor day

Yahoo Finance Video

7 months ago

Lyft stock earns multiple upgrades after investor day

Finally, I can make my iPhone look like total crap

Engadget

7 months ago

Finally, I can make my iPhone look like total crap

Stock Split Watch: 3 Growth Stocks That Could Be Next

Motley Fool

7 months ago

Stock Split Watch: 3 Growth Stocks That Could Be Next

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

GlobeNewswire

7 months ago

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

PR Newswire

7 months ago

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen

Business Wire

7 months ago

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

GlobeNewswire

8 months ago

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

8 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term

Simply Wall St.

8 months ago

Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term

GuruFocus.com

8 months ago

Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...

Travere Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire

8 months ago

Travere Therapeutics Reports First Quarter 2024 Financial Results

Travere Therapeutics to Report First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Travere Therapeutics to Report First Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

GlobeNewswire

9 months ago

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

PR Newswire

9 months ago

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

GlobeNewswire

9 months ago

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

GlobeNewswire

10 months ago

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

GlobeNewswire

10 months ago

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

GlobeNewswire

a year ago

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

CNW Group

a year ago

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

PR Newswire

a year ago

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

AMERANT BANK PROVIDES FINANCING TO FRESCO RETAIL GROUP, LLC FOR THE ACQUISITION OF FRESCO Y MÁS OPERATIONS AND LOCATIONS

GlobeNewswire

a year ago

AMERANT BANK PROVIDES FINANCING TO FRESCO RETAIL GROUP, LLC FOR THE ACQUISITION OF FRESCO Y MÁS OPERATIONS AND LOCATIONS

BlueLinx Holdings Inc.'s (NYSE:BXC) Intrinsic Value Is Potentially 21% Below Its Share Price

Simply Wall St.

a year ago

BlueLinx Holdings Inc.'s (NYSE:BXC) Intrinsic Value Is Potentially 21% Below Its Share Price

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

GlobeNewswire

a year ago

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

ConnectOne Bancorp Inc Reports Mixed Results Amid Industry Challenges

GuruFocus.com

a year ago

ConnectOne Bancorp Inc Reports Mixed Results Amid Industry Challenges

GuruFocus.com

a year ago

First Bancshares Inc (FBMS) Reports Mixed Quarterly Results and Yearly Growth Amid Market Challenges

Associated Press Finance

a year ago

ConnectOne: Q4 Earnings Snapshot

ConnectOne Bancorp, Inc. Reports Fourth Quarter and Full-Year 2023 Results; Declares Common and Preferred Dividends

GlobeNewswire

a year ago

ConnectOne Bancorp, Inc. Reports Fourth Quarter and Full-Year 2023 Results; Declares Common and Preferred Dividends

The First Bancshares (FBMS) Lags Q4 Earnings and Revenue Estimates

Zacks

a year ago

The First Bancshares (FBMS) Lags Q4 Earnings and Revenue Estimates

2 Financial Stocks to Buy After Massive Earnings Beats

Zacks

a year ago

2 Financial Stocks to Buy After Massive Earnings Beats

Veritex Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

GlobeNewswire

a year ago

Veritex Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

ALLIANCEBERNSTEIN CLOSED-END FUNDS ANNOUNCE DISTRIBUTION RATES

PR Newswire

a year ago

ALLIANCEBERNSTEIN CLOSED-END FUNDS ANNOUNCE DISTRIBUTION RATES

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

PR Newswire

a year ago

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

Establishment Labs Announces Commercial Launch of Motiva Implants in China

Business Wire

a year ago

Establishment Labs Announces Commercial Launch of Motiva Implants in China

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024

PR Newswire

a year ago

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024

LanzaTech Global, Inc. (NASDAQ:LNZA): When Will It Breakeven?

Simply Wall St.

a year ago

LanzaTech Global, Inc. (NASDAQ:LNZA): When Will It Breakeven?

11 Stocks That Will Make You Rich in 5-10 Years

Insider Monkey

a year ago

11 Stocks That Will Make You Rich in 5-10 Years

Service Properties Trust Announces 2023 Dividend Allocation

Business Wire

a year ago

Service Properties Trust Announces 2023 Dividend Allocation

Investors in Equinox Gold (TSE:EQX) have unfortunately lost 51% over the last three years

Simply Wall St.

a year ago

Investors in Equinox Gold (TSE:EQX) have unfortunately lost 51% over the last three years

Upwork Inc. (UPWK) Hit a 52 Week High, Can the Run Continue?

Zacks

a year ago

Upwork Inc. (UPWK) Hit a 52 Week High, Can the Run Continue?

Apple’s VP of finance is the new CFO at Sonos. Here’s what prepared her for the role

Fortune

a year ago

Apple’s VP of finance is the new CFO at Sonos. Here’s what prepared her for the role

NETSTREIT Corp. Announces Pricing of Upsized Forward Common Stock Offering

Business Wire

a year ago

NETSTREIT Corp. Announces Pricing of Upsized Forward Common Stock Offering

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Business Wire

a year ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Travere Therapeutics Provides Corporate Update and 2024 Outlook

GlobeNewswire

a year ago

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

PR Newswire

a year ago

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

Shipping stocks jump as freight costs soar amid Red Sea tensions

Yahoo Finance

a year ago

Shipping stocks jump as freight costs soar amid Red Sea tensions

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Is There An Opportunity With Monarch Casino & Resort, Inc.'s (NASDAQ:MCRI) 28% Undervaluation?

Simply Wall St.

a year ago

Is There An Opportunity With Monarch Casino & Resort, Inc.'s (NASDAQ:MCRI) 28% Undervaluation?

WalkMe Survey Shows Half of Workers Don’t File Expense Reports, Leaving Billions of Dollars on the Table

GlobeNewswire

a year ago

WalkMe Survey Shows Half of Workers Don’t File Expense Reports, Leaving Billions of Dollars on the Table

Here's Why We Think Cheesecake Factory (NASDAQ:CAKE) Is Well Worth Watching

Simply Wall St.

a year ago

Here's Why We Think Cheesecake Factory (NASDAQ:CAKE) Is Well Worth Watching

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

GlobeNewswire

a year ago

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

TriMas Packaging Selected to Partner With Leading Food and Beverage Brands

Business Wire

a year ago

TriMas Packaging Selected to Partner With Leading Food and Beverage Brands

12 Best Junior Silver Mining Stocks To Buy Now

Insider Monkey

a year ago

12 Best Junior Silver Mining Stocks To Buy Now

GlobeNewswire

a year ago

Oxford Lane Capital Corp. Provides November Net Asset Value Update

PR Newswire

a year ago

SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR DECEMBER 2023

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

GlobeNewswire

a year ago

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

Share on Social Networks: